Subscribe
Michael Vi / Shutterstock.com
7 October 2025NewsAmericasMarisa Woutersen

Eli Lilly strikes AI drug discovery deal with US biotech

The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
As AI shakes up pharma and biotech, can patent law keep up?
22 May 2025   Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025   Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025.
Americas
Strategic IP protection for biotech-related GenAI
24 April 2025   Generative AI is transforming the biotech industry, so it’s crucial to have an IP strategy—in particular, for trade secret and/or patent protection. Dean Pelletier of Pelletier Law explains.


Editor's picks

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025

Editor's picks

Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025

More features

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
Why AI is changing the patent rules faster than anyone can keep up
The hidden code in life sciences deals
LSPN panel unpacks critical IP risks in deal-making
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Less is more: patent lawyers flip the script after Amgen
‘Doing more with less’: In-house counsel on budgets and strategy
End of the ‘Death Squad’? Squires puts PTAB on trial